The last years have seen an incredible advancement in the field of multiple sclerosis (MS). Xavier Montalban, MD, PhD, MBA, Vall d’Hebron University Hospital, Barcelona, Spain, gives an overview of the current diagnostic and therapeutic scene in MS. Firstly, Prof. Montalban highlights the advancements in the diagnosis of MS, which have facilitated early diagnosis and enabled early treatment, positively impacting the long-term prognosis of MS patients. Additionally, monitoring of relapsing MS therapies has greatly improved as well as the number of therapies available to treat those patients. Progressive disease remains a challenge, and future research will focus on treatments that can halt or even reverse disease progression. Finally, Prof. Montalban shares anticipated developments in the field of MS, such as tools to measure progression. This interview took place during the XXV World Congress of Neurology.
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.